Retatrutide: A Research Compound Overview

Retatrutide (LY3437943): A Research Overview

Retatrutide is a synthetic triagonist peptide that simultaneously activates three incretin and metabolic receptors: GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and GCGR (glucagon receptor). Developed by Eli Lilly, it represents the next generation of incretin-based metabolic research tools. Its triple-receptor activity profile makes it one of the most studied compounds for metabolic syndrome, obesity biology, and hepatic steatosis research.

Research Applications

• Triple incretin receptor activation and downstream cAMP signaling studies
• Adipose tissue lipolysis via GCGR-mediated energy expenditure research
• Pancreatic beta-cell glucose-dependent insulin secretion (GSIS) models
• Hepatic fat metabolism and NASH/NAFLD pathology models
• Central appetite regulation via GLP-1R-mediated satiety signaling
• Energy expenditure and thermogenesis via glucagon receptor activation
• Cardiovascular risk marker modulation (LDL, triglycerides, blood pressure)

Molecular Profile

• Type: Acylated peptide triagonist (GLP-1R / GIPR / GCGR)
• Molecular Weight: ~4856 Da
• CAS Number: 2381272-07-5
• Half-life: ~6 days (subcutaneous, human) via C18 fatty acid albumin binding
• Receptor Affinity: GLP-1R Ki ~0.6 nM · GIPR Ki ~0.7 nM · GCGR Ki ~1.0 nM
• Format (Official Peptides): Lyophilized powder, >99% HPLC

Mechanism of Action

Retatrutide's triagonist activity enables complementary mechanisms not achievable with mono- or dual-agonists. GLP-1R activation reduces food intake and slows gastric emptying via central and peripheral pathways. GIPR co-activation enhances the insulinotropic response. GCGR activation drives lipolysis, thermogenesis, and hepatic lipid clearance, creating a net energy deficit additive to GLP-1R-mediated appetite suppression. The C18 fatty acid moiety enables albumin binding and extended half-life suitable for once-weekly dosing in animal models.

Research Considerations

Retatrutide's multi-receptor profile requires careful experimental design to isolate individual receptor contributions. Selective receptor antagonists (exendin(9-39) for GLP-1R; [D-Ala²,Glu⁹]-Glucagon for GCGR) are recommended for mechanistic dissection. Given sub-nanomolar EC₅₀ values at all three receptors, very low concentrations are effective in cell-based assays; titration controls are essential to avoid receptor desensitization artifacts.

For in vitro laboratory research only. Not for human consumption. Not FDA approved.